Castle Biosciences has released data from a multi-centre DECIDE study showing the impact of integrating its DecisionDx-Melanoma test results into clinical decision-making in melanoma patients.

TissueCypher is Castle’s precision medicine risk-stratification test that predicts a patient’s individual risk of progression from Barrett’s esophagus (BE) to esophageal cancer Castle ...

Did you know that quizzes can boost your memory, sharpen your focus, and expand your knowledge in just a few minutes? Whether ...

Statewide numbers suggest student test scores have flatlined in Hawaii in recent years, but results for individual schools ...

An East Side man was arrested Tuesday after police pulled him over, reportedly for his fifth driving under the influence offense, last week.

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating ...

When Gregg Popovich announced before the game that Spurs backup point guard Tre Jones would be out for two weeks with an ankle injury, expectations rose that rookie Stephon Castle would get more ...

Like a scene out of Scooby Doo, the group of 12 trainee guide dogs visited Warwick Castle's Halloween trail as a way to prepare them for remaining calm in unusual environments, where the ...

About TissueCypher® Barrett’s Esophagus Test The TissueCypher Barrett’s Esophagus test is Castle’s precision medicine test designed to predict future development of high-grade dysplasia ...

The TissueCypher Barrett’s Esophagus test is Castle’s precision medicine test designed to predict future development of high-grade dysplasia (HGD) and/or esophageal cancer in patients with ...

TissueCypher is Castle’s precision medicine risk-stratification test that predicts a patient’s individual risk of progression from Barrett’s esophagus ...